Markus
I should have given citations to my praise of Erbitux since that phrase was hardly original but widely quoted. There were just so many to choose from but let's use the gold standard, the OCF reader Oral Cancer News on Oct 15th:
"Merck Serono�s Erbitux� is one of the finalists for the prestigious International Prix Galien Award for excellence in pharmaceutical development and innovation due to its role in transforming the treatment of head and neck cancer.

Erbitux is the first and only targeted therapy approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) and works in a completely different way to conventional chemotherapies. Through its targeted mode of action, Erbitux blocks the epidermal growth factor receptor (EGFR), which is expressed in more than 90% of SCCHN tumors1 and is directly related to a poor prognosis for patients. The efficacy and tolerability of this novel drug have been shown in clinical trials2 - the latest of which, EXTREMEa, demonstrated the first significant advance in 30 years for the treatment of recurrent and/or metastatic SCCHN. "
My CCC is tracking me as part of their studies to get meaningful statistics for Erbitux /IMRT to go with their ongoing clinical study on platinum/IMRT vs Plat+Erb/IMRT. As noted above, the 90% figure for head & neck is a lot better than than the 40% for breast cancer MAB.

Angel
I should have mentioned a warning that if you have lived anywhere where there are a lot of "seed ticks" - such as Georgia or Tennessee - and you were bitten a lot hiking by seed ticks, then Erbitux is not for you as that is the number one cause of a bad reaction. Seems that the antibodies you develop from the tick bites mess up the MAB action. My CCC quizzed me about this and they won't use it on patients who came in from those southern states even though the conclusive studies are still being done, My experience was just with the old fashioned grown up ticks in the Northeast, so no problem.